Tempus AI, Inc. (TEM) Earnings Call Transcript & Summary
August 6, 2024
Earnings Call Speaker Segments
Liz Krutoholow
executiveThanks. Good afternoon, everyone, and thanks for joining Tempus' call for the second quarter of 2024. Earlier today, Tempus put out its results for the quarter that closed on June 30, 2024. Here with me from Tempus are Eric Lefkofsky, our Founder and CEO, and Jim Rogers, our CFO. Before we get started, I want to note that on this call, management might make forward-looking statements, and those carry risks and uncertainties that may lead actual results to differ materially; to review those risks, please see our 10-Q covering the quarter that ended June 30, 2024, which was filed on August 6, 2024, along with any upcoming reports we submit to the SEC. On this call, we'll also talk about non-GAAP financial measures, and those aren't prepared under generally accepted accounting principles. You can find definitions of those non-GAAP financial measures, plus reconciliations to the GAAP financial measures that are most directly comparable, in our second quarter earnings release, which we've furnished to the SEC and which you can access on our website at investors.tempus.com. At this point, I'd like to hand the call over to Eric.
Eric Lefkofsky
executiveTo start, I want to welcome everyone to our first earnings call since becoming a public company. We're glad to be here and ready to take your questions. Maybe I'll take about 30 seconds to share a bit of context. Q2 was a solid quarter, and we gave some extra detail in our overview letter. Our core businesses are still on track. Things look the way you'd hope — moving up and to the right — and we're executing just as we planned, both when we started the process of going public a few months back and certainly as we moved through the quarter. So I'd say we feel we're in a good place, and we're happy to answer whatever questions anyone has.
Liz Krutoholow
executiveOperator, we can open the line for questions, please.
Tejas Savant
analystCongratulations on a strong debut following the IPO. Eric, perhaps you or Jim could weigh in on this. There was nice movement on ASPs on the Genomics side during the quarter. Could you take us through your thinking regarding possible SDFs upside in the second half of the year? You also have the ADLT rate on xT coming through, but it would be great to hear any color on how much of that is already assumed versus advancement on the commercial payer front.
Eric Lefkofsky
executiveOkay, I'll begin by addressing the core Genomics business and volumes, and Jim can speak a bit about reimbursement. Regarding the overall strength of our units and unit growth, as we discussed in our overview letter, we believe we are fully on track. We delivered approximately 4,000 additional tests during the quarter in Q2 compared with Q1. That trend should keep going, in our view. There is, of course, some percentage seasonality in the growth rate, since a quarter may contain fewer days or ASCO may land at a different point, which can have an effect; even so, we believe our — the core Genomics business is doing what we anticipated, and we believe we can achieve that 25% to 30% growth range for units. Given our size and scale, we are certainly among the largest therapy selection sequencers in the market at this stage, and we think that is a very healthy position. As for ASP and reimbursement, I'll turn things over to Jim.
Jim Rogers
executiveAbsolutely, and thanks for raising that, Tejas. In Q2, our reimbursement averaged roughly $1,500, which is up around $50 compared with what we saw in Q1 of 2024. What mainly fueled that increase was a modest shift in mix toward more Medicare and Medicare Advantage patients, since those groups usually reimburse at a higher level than what commercial payers give us. Just to remind everyone, with commercial payers we operate largely as an out-of-network provider. That means our average reimbursement comes in much lower than what Medicare pays us. Looking ahead, that creates an opportunity as we work through negotiations with those payers to get coverage for the different tests we currently have on the market. Tejas, you also brought up the ADLT status for our xT CDx assay, the FDA-approved form of xT. At the outset, the price was established at $4,500, though that pricing determination will unfold across the latter half of this year. As a result, ASPs in 2024 won't see any significant effect tied to the FDA-approved version. However, once we begin shifting volume toward that version of the assay in early 2025, we ought to gain some extra tailwinds.
Tejas Savant
analystUnderstood. That helps. Now, everyone, I'd like to probe a bit more regarding the MRD launch. Is there any early anecdotal input from customers that you're able to pass along? Any kinds of distinctions you want to highlight, plus how the tumor-naive option has been received compared with NeXT Personal at this point? Also, what's your thinking on how much volume MRD will add during the back half of the year? And is reimbursement basically something that plays out in the back half of 2025? Or might it come earlier than that?
Eric Lefkofsky
executiveYes. Once more, I'll handle the launch in general, and perhaps Jim can address a few points about reimbursement. So we launched — for anyone unaware, we basically introduced our full MRD platform at ASCO, featuring a tumor-naive assay for colorectal cancer. And then, working alongside Personalis, we also commercialized breast, lung, and IO with a tumor-informed assay. The — I believe the reaction has been very favorable, even though both of us are currently limiting volume, because if we simply threw the doors wide open, you'd probably see a huge amount of volume that right now isn't reimbursed; so since securing reimbursement takes time, we're releasing accounts we make the assay available to in a controlled way and increasing gradually, which lets us manage the cost side of building the tested market. Even so, all the anecdotal feedback we receive is extremely favorable. I think two, as I've mentioned to many people before, tumor naive has a role in the market, because from a logistical and administrative standpoint, it's simply simpler than tumor informed for numerous accounts that can't perform another biopsy or lack sufficient tissue to essentially conduct a second round of sequencing, which uses up a great deal of tissue whenever you sequence a patient; so if you've already done therapy selection, doing MRD once with an informed assay can create logistical difficulties. So I believe naive has a role. And then the subsequent assay Personalis has introduced, which we're clearly involved with, is genuinely ultrasensitive; therefore there's a role for that too, where people are truly seeking that ultra sensitivity and specificity along with genuine limits of detection; and so I think you — we have a — we believe we've got a really strong MRD lineup on the market, with a highly practical logistical product and a highly ultrasensitive product, and we think we can serve the market's needs throughout that range, but we don't increase those units for that volume until reimbursement is within reach. And perhaps Jim can offer us a few remarks about that.
Jim Rogers
executiveYeah. As far as getting paid for the tumor-naive panel we developed in-house, we're putting that submission together for MoldX at this moment. After that, the review will take its course. So Tejas, you brought up roughly the second half of 2025. That's usually how long it takes, in my view, though we'll definitely share additional detail once that process moves forward.
Rachel Vatnsdal Olson
analystGreat; so to start, regarding how Genomics did this quarter, it was up 22% versus the prior year, and you said every test did well this quarter, but I wanted to see if you might break that down a little further for us? Take us through, even at a high level, how each test did in 2Q; and then, were there any meaningful changes when it came to how much volume each test contributed too?
Eric Lefkofsky
executiveYeah, there was — I mean, nothing significant in the sense of some kind of systemic change in the way orders came in. We've got a platform that's — we're in inherited cancer risk, we're in solid tumor profiling, and liquid biopsies. So we basically cover all 3 quite broadly. And I'd say all are sort of doing what they've done historically when it comes to both units and revenue growth. There hasn't been — there was no huge cyclical swing like suddenly our solid tumor went one direction or liquid went another; they're all sort of heading the same way; they were moving in — clearly — or not clearly, but liquid for us was a newer product compared with solid. Solid was the first assay we launched, and liquid came after. And so that product's growth rates have historically been greater. But ultimately, as these products now reach scale, and we are at scale when it comes to ctDNA assays, we're at scale when it comes to solid tumor for profiling, and getting close to scale at inherited cancer risk, I'd expect that the growth rates will begin to normalize so you won't see very big differences among the 3 as we continue getting larger. And I think we've also said historically that liquid was roughly 1/4 of our volume and it stays that way. There's been no systemic change there.
Rachel Vatnsdal Olson
analystGreat. All right, that's useful. Then for my follow-up, could you give us a breakdown of the Data revenues split between Insight trials and AI Applications for 2Q? And when I look at the guidance, you directed us toward that $700 million figure for revenues for the year — how should we think about that mix between Data and the Genomics business? And is there any seasonality we ought to keep in mind across 3Q and 4Q for each of those segments too?
Eric Lefkofsky
executiveI'll handle the first portion, and Jim can address the second portion, which appears to be a recurring theme today. So regarding the Data business, which, clearly, has growth that is accelerating, we gave some color that Insights was the leader. We had a very strong quarter for Insights, which is our data licensing business. The Trials business did grow, but its growth was slower than our data licensing product, Insights. Insights also carries a much higher margin. So to the degree we want a portion of our Data and services business to grow, we want the Insights piece growing; it has the highest margin, and it's the one we devote a lot of time and focus to. Our Trials business really consists of a few components. It consists of our just-in-time network, which we refer to as TIME. It consists of the small studies component, and it also consists of our CRO business that we named Compass, and we are not investing as heavily in growing our CRO. It isn't a core part of our growth strategy. It's an important component of what we do, but it isn't something we focus on growing as much as we do, for instance, our Insights business. So I would expect that over time, if we continue to deliver, Insights will keep outpacing our Trials business, and so I would expect that will be a trend we see going forward as well.
Jim Rogers
executiveAbsolutely. Let me give you a bit more texture around those figures. The Insights segment accounts for roughly 75% of the revenues from Data and services, and as Eric mentioned, it's also the fastest-growing piece among those parts. When it comes to total revenue of approximately $700 million for the full year 2024, the historical pattern has been a 2/3, 1/3 division — 2/3 from Genomics and 1/3 from Data and services. Clearly, the Data and services portion is expanding at a quicker pace than the Genomics side. As a result, for the rest of the year, we'd lean somewhat more toward the Data side of the business rather than Genomics.
John Kim
analystJohn Kim here, filling in for Mike. Is there anything new regarding the Guardant lawsuit? I realize resolving it will likely require several years, but I did want to check whether you have any fresh information.
Eric Lefkofsky
executiveNothing new to report. A significant development probably won't come unless something occurs — resolving these matters takes a very long time. Consistent with what we've stated before, we don't view it as material. Our defenses strike us as adequate, and this isn't a matter causing us excessive worry. My expectation is that it will require years to reach a conclusion. Sadly, within our industry, litigation has become a widespread element across much of what happens, and I'd anticipate that pattern persisting simply due to the nature of things; however, our attention remains on doing what benefits patients; our attention remains on ensuring our tests lead the market and that patients can obtain them, and that's the area we keep <<inaudible>>.
John Kim
analystUnderstood. And on the cost side, those landed right in line with what we'd anticipated. That said, as we look forward, you also provided the EBITDA guidance. Do you have any updated thinking on the timing — has anything shifted in your view regarding when adjusted EBITDA profitability will be reached?
Eric Lefkofsky
executiveBroadly speaking, I'd say we delivered what I consider quite substantial advancement during the quarter. I mean, we stood at 12.5...
Jim Rogers
executive$12.7 million.
Eric Lefkofsky
executiveThat's a $12.7 million gain compared with the prior quarter. So, as we've communicated to everyone, we believed that operating leverage was becoming visible in our operations, and I think Q2 proved that point. We'd expect still more leverage to emerge as growth continues. Consequently, we believe we remain exactly where we should be.
Dan Brennan
analystCongratulations on the quarter and on the IPO. Your prepared remarks and the script posted on the website contain quite a bit of detail about the Insights business and some newly signed contracts. Could you perhaps elaborate on that a bit? Starting with Novartis, which you mentioned — you'll be delivering that across 2024. Can you help us get a sense of how large that contract is, or share any specifics about it? Then there's the new 5-year agreement with Takeda, which you described as a big expansion in both size and scope. Could you give us some color on that one and how we should think about its scale?
Eric Lefkofsky
executiveYes. Obviously, for a number of reasons, we didn't put numbers in — not least because we're mindful of the fact that we have partners involved in these matters. Sometimes it's suitable to share them. Sometimes it isn't. All of these are sizable deals for us. What I think we conveyed for the quarter is that we had several large pharma companies, and we didn't name all the smaller biotechs we also entered various agreements with — but we had roughly 4 larger pharma companies that each completed meaningful deals during the quarter. For us, that was simply a signal of both the revenue we generated in our Insights business and the bookings we generated — Q2 was a very strong quarter for data licensing, and it was encouraging to see that. We anticipated it, it was encouraging to see it, and we expect that momentum to keep going, at least for the foreseeable future. However, we don't typically discuss how big these deals are unless they become so large that we essentially have no alternative; and these were genuinely good-sized deals, but they weren't $300 million deals where we'd be — talking about a <<inaudible>> deal.
Jim Rogers
executiveOn top of that, let me mention that the overall value left on our contracts continues to exceed $900 million. So once more, like Eric said, we brought in quite a bit of revenue, yet ad bookings essentially replenished that overall remaining contract value; the other figure, which we share each year, is net revenue retention, but these once again are the standout examples where we had agreements locked in, and we managed to grow them in later years. So every deal referenced in the release has us feeling optimistic.
Eric Lefkofsky
executiveRight, and just to build on what Jim said, one of the most thrilling aspects of the Astellas indicated arrangements, along with Novartis', is that these are organizations that already had multiyear deals and are re-upping for bigger agreements, or we're upping for longer stretches. That's exactly the kind of thing you hope to see — Tempus is just 8 years old, correct? We've been in the data licensing business for 5 or 6 years, so what you're looking for — and this means that the majority of these — most of our customers have been customers for only 2 or 3 years on the data side. So watching major renewals happen time and time again is a genuinely strong indicator that we're delivering enormous value, and that value is connecting with our plans.
Dan Arias
analystEric, regarding what you mentioned about data contracts, a question we received while going through this was about that more than $900 million of revenue already under contract — and that figure includes $300 million tied to customers who have not officially renewed. Could you speak to how confident you feel about getting those 2 accounts to sign again? And could you also remind us of when those agreements are actually up for renewal?
Eric Lefkofsky
executiveSure. In fact, for both contracts, the timing has already been pushed out through amendments. As I recall, one of those amendments tacked on an additional year for AstraZeneca, along those lines. And with GSK, we now have a longer term extending further out. So we're looking at — I can't recall the specific dates, but approximately 2027, '28, summer of '27, '28. Those contracts therefore stretch several years into the future, meaning nothing is expiring right away, and we're confident about every one of our bigger deals when it comes to the value we provide, and our expectation would be that nearly all of our large deals get renewed and, we hope, grow larger.
Dan Arias
analystYes. All right. Then, just to follow up about that excess asset — do you figure you'll be filing it during this quarter? Or should we instead assume it happens before the year wraps up?
Jim Rogers
executiveMy apologies, Dave — I missed that question. Could you repeat it?
Eric Lefkofsky
executiveToo much of what, exactly?
Dan Arias
analystRegarding sending the assay over to the FDA — my understanding was that this is something currently in progress. What I'd like to know is whether you expect that hurdle to be cleared within the coming 2 months, or does it look more like December?
Eric Lefkofsky
executiveThe precise schedule isn't something I can give you, though those teams are preparing a filing that should arrive quite soon. For us, I'd say the larger matter involves both RNA and our liquid biopsy — we have teams dedicated to filing for each of them. And whether that lands 1 quarter out or 2 quarters out, everything here is essentially on the verge of happening.
Andrew Brackmann
analystPerhaps regarding the rep side, I understand you brought on some — or I believe it was roughly 30% during the early portion of the year, so could you provide an update on how productive that new cohort has been, and also address any sales force adjustments or disruptions that might come about because of it?
Eric Lefkofsky
executiveYeah. Productivity isn't where we'd like it to be, frankly. That's my most polite way of putting it. We brought on — I believe the figure was nearer to 60 rather than 30, when it comes to total heads added over a relatively brief span throughout the whole sales infrastructure. So we brought on quite a few people during the first half of this year. We implemented numerous territory changes. We rolled out a new assay. And combining bringing on many people, altering many territories, and rolling out a new assay means our sales force efficiency in Q2 wasn't at the level we'd like. We keep seeing gains, and I'm sure we'll return to where it was in Q3 or soon after. But ultimately, when you're expanding as fast as we are and you're bringing in a lot — a bunch of new assays, occasionally, you encounter these step functions and territorial change, and you have to handle it very well. And we're a young company, and we'll always have some quantity of bumps to overcome. We notice it in the numbers. We sort of — as you can observe the numbers, we handled all of that and still expanded the Genomics business at 22%. So we feel good about it.
Andrew Brackmann
analystGreat. And then perhaps regarding the PurIST algo, to start, could you remind everyone why that test matters so much for your portfolio and in what way it might set you apart? And then, you also got the PLA code during the prior month, so what's your thinking around securing possible reimbursement there, or being somewhat first in line to get reimbursement for these AI tests?
Eric Lefkofsky
executiveYeah, it was quite thrilling to become the first firm ever to have a code on these algorithms and reach this stage. That's really neat. When I look at this business and at our apps operations more generally, I think we're fortunate to own a Genomics unit that is in good shape, expanding, and delivering strong margins. We also have a Data operation that is in good shape, expanding, and delivering strong margins. That means, over the short term, generating substantial revenue from our apps business isn't something we depend on — which is quite beneficial, since neither our nation nor our health care system has worked out a way to fund AI; no one has settled the question of when it ought to be requested. Nobody has determined the right way to provide it. Nobody has determined the right way to finance it. The whole area is simply too new. We're definitely encouraged that so many of these codes are being issued and that doctors are interested in this type of algorithmic diagnostics. That said, there's still a lot of work ahead of us when it comes to figuring out how these tests fit into the guidelines, how they become part of routine practice, and ultimately how we secure reimbursement for them. My guess is that this will take several years. On top of that, our cardiac algorithm designed to predict atrial fibrillation also received FDA approval, which is fantastic. But once again, no reimbursement pathway exists for that test at the moment. So we have to focus on demonstrating — and obviously, analytical validity has already been demonstrated. At this point, we need to show that these tests work clinically and, in the end, get payers on board that covering them makes sense for them financially. That's something we'll be working at over several years. My guess is that we'll keep launching a lot of algorithms. What we're aiming for is a really wide-ranging lineup of algorithmic diagnostics within our Applications business, and to start down the road toward reimbursement. If things go our way, this could grow into a substantial business down the line. As we've mentioned before, this could end up being much bigger than our other operations. That said, it's a lengthy process, and I'm not able to say whether we're half a year or a full year out from finally spotting some progress — it's simply too early to tell. So, as you're aware, we'll keep you posted.
Analyst
analystCongratulations on both the quarter and the IPO. Eric, to follow up on what was asked before, I'd like to hear your thoughts on how quickly the emerging AI Applications business is being adopted. I realize it's still very early, but perhaps you could describe what you observed during the quarter in that area; and then maybe expand a bit on the work and programs aimed at bringing those solutions into the health care ecosystem, if you don't mind.
Eric Lefkofsky
executiveSure. This is — the story is quite promising, but revenue-wise it remains extremely small; thus while our Applications business is growing at a very rapid clip, it's likewise fairly modest in size since, as I said, we, being a health care system, have not yet worked out a way to fund many of these applications. So the main pieces of our Apps business at present, our Applications business at present, we are the largest next, through which we're essentially resolving care gaps as they happen, and beyond that we have a set of algorithms, be it in digital pathology or cardiology, that likewise rely on algorithms. But consider, say, Next alone, just that single product — it's a remarkable product because we can examine clinical data as it comes in, data that's more or less real time, and identify basically errors or mistakes as they occur, in situations where guidelines exist and practice is routine; and still, for whatever reason, a particular patient has slipped through a care gap. That's something that occurs in health care. It's simply how the system works. Nobody is flawless. Deploying AI and technology to catch those and attempt to fix them is extremely powerful when it comes to the value delivered to patients and physicians. Getting compensated for it, however, is somewhat more difficult. And so once more, we're seeing, I'd call them, very encouraging, robust signals of adoption. These sorts of applications are wanted by people. They're eager to put them to use. We're achieving enormous progress, yet a considerable amount of effort remains on our part as a system — not only Tempus, but anybody involved in AI in health care — to have these things funded at scale. And that is the thing that moves us from a high growth but small business into a high growth and large business.
Ryan MacDonald
analystCongratulations on a strong quarter and a successful IPO. Eric, I'm somewhat interested in this—on the health care IT side, we've seen the data segment as one that's faced real difficulty when it comes to how much investment or spending many large pharmas and biotechs are prepared to set aside this year compared with other vendors. Could you explain why you've managed to achieve such strong results in the data portion of the business, and how you stand apart there? And then perhaps, during the quarter, regarding the combination of expansions versus brand-new logos you added within the Data business.
Eric Lefkofsky
executiveYes. What I'd say is that we're seeing genuinely favorable momentum and quite robust expansion in our Data business, and I'd argue this is happening against a very difficult backdrop. I believe you pointed that out. The macro conditions, after all, aren't good. You've got biotechs, particularly the smaller ones, that have struggled enormously to raise capital over the last several years; meanwhile big pharma has been extremely careful regarding its R&D budgets. Even so, we're expanding very rapidly and we keep signing major deals in spite of what I'd describe as a hard environment. So my hope is that over the next year or 2, once conditions shift—and I'm confident they will shift. Eventually biotech will be able, I believe, to return to the public markets and raise capital, and I think that will give that business a genuinely favorable tailwind. Yet ultimately, the reason I believe we're expanding comes down to a very straightforward formula. When you provide something valuable that customers actually want, something that assists them in strengthening their early-stage discovery work, strengthening their capacity to design clinical trials, strengthening their capacity to develop assets more efficiently and bring them to market, to get clinical trials done and closed faster, all of these matter enormously and businesses will pay, but you must prove that value. So when markets get harder, you get a distinction between nice-to-have and need-to-have. And right now, at least, Tempus represents need-to-have data for plenty of customers. And I think you're correct—they're likely trimming budgets for the nice-to-have items.
Ryan MacDonald
analystThat's really useful context. Let me ask something else. Turning to Genomics — with all the encouraging developments you keep getting when it comes to CMS reimbursing for assays, could you describe how you're approaching the use of that in conversations with commercial payers as a way to maybe secure better reimbursement? And where would you say we are in terms of how far along those talks have gotten?
Jim Rogers
executiveSure. On the commercial payer front, I'd say we're definitely traveling the same path that basically every sequencer has traveled. Securing CMS coverage is a big deal; that opens things up, along with FDA approval. At some point that opens up the chance to hold these conversations with commercial payers; we've entered network agreements with Cigna, Humana and Aetna, so some headway has been made. Even so, there's still a great deal left to do. And we are holding those conversations, but resolving them simply takes quite a while. So in the coming few quarters, we'll definitely provide updates on how things are going <<inaudible>>.
Operator
operatorEveryone, that wraps up our session for today. Thanks to each of you for being here. You're free to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Tempus AI, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Tempus AI, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Tempus AI, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.